Resolution of sexual dysfunction during acute treatment of major depression with milnacipran
Resolution of sexual dysfunction during acute treatment of major depression with milnacipran
Objective
The sexual function and enjoyment questionnaire (SFEQ) was developed to assess and detect changes in sexual function in men and women. The aim of the present study was to use the SFEQ to evaluate the effects of the serotonin-noradrenaline reuptake inhibitor, milnacipran, in the treatment of depression in two culturally different populations.
Methods
The SFEQ was employed in two studies investigating milnacipran in the treatment of major depression: a 12-week open study in Brazil and a 6-week randomised controlled study in Europe.
Results
At endpoint, 61.3% (Brazil) and 78.4% (Europe) of patients had 50% reduction of baseline Hamilton Depression Rating (HAMD) score. All SFEQ items showed improvements in sexual function in both studies at endpoint, 60% (Brazil) and 56% (Europe) of patients stating that their sexual desire was as great as or greater than it had been before their depressive episode.
Conclusions
Milnacipran appears to improve sexual function in parallel with improvement in other symptoms of depression. The SFEQ is a sensitive instrument for measuring changes in sexual function and appears to be unaffected by cultural differences as shown by similar findings in Brazil and Europe.
depression, treatment, sexual dysfunction, paroxetine
527-532
Baldwin, David
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Moreno, Ricardo A.
ebe4acbf-43bb-4a29-ad01-9959e0b6ef76
Brilley, Mike
f6626f28-742f-4f4b-a597-bf71903c9834
August 2008
Baldwin, David
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Moreno, Ricardo A.
ebe4acbf-43bb-4a29-ad01-9959e0b6ef76
Brilley, Mike
f6626f28-742f-4f4b-a597-bf71903c9834
Baldwin, David, Moreno, Ricardo A. and Brilley, Mike
(2008)
Resolution of sexual dysfunction during acute treatment of major depression with milnacipran.
Human Psychopharmacology: Clinical and Experimental, 23 (6), .
(doi:10.1002/hup.955).
Abstract
Objective
The sexual function and enjoyment questionnaire (SFEQ) was developed to assess and detect changes in sexual function in men and women. The aim of the present study was to use the SFEQ to evaluate the effects of the serotonin-noradrenaline reuptake inhibitor, milnacipran, in the treatment of depression in two culturally different populations.
Methods
The SFEQ was employed in two studies investigating milnacipran in the treatment of major depression: a 12-week open study in Brazil and a 6-week randomised controlled study in Europe.
Results
At endpoint, 61.3% (Brazil) and 78.4% (Europe) of patients had 50% reduction of baseline Hamilton Depression Rating (HAMD) score. All SFEQ items showed improvements in sexual function in both studies at endpoint, 60% (Brazil) and 56% (Europe) of patients stating that their sexual desire was as great as or greater than it had been before their depressive episode.
Conclusions
Milnacipran appears to improve sexual function in parallel with improvement in other symptoms of depression. The SFEQ is a sensitive instrument for measuring changes in sexual function and appears to be unaffected by cultural differences as shown by similar findings in Brazil and Europe.
This record has no associated files available for download.
More information
Published date: August 2008
Keywords:
depression, treatment, sexual dysfunction, paroxetine
Identifiers
Local EPrints ID: 62235
URI: http://eprints.soton.ac.uk/id/eprint/62235
ISSN: 0885-6222
PURE UUID: 57426a6a-3d12-4c9c-8eec-bcdf55ef5e58
Catalogue record
Date deposited: 01 Sep 2008
Last modified: 16 Mar 2024 02:48
Export record
Altmetrics
Contributors
Author:
Ricardo A. Moreno
Author:
Mike Brilley
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
